Risk nomogram for assessing renal recovery in patients with newly diagnosed multiple myeloma-related renal impairment

被引:0
|
作者
Li, Shaobo [1 ,2 ]
Zhang, Min [3 ]
Liu, Jin [4 ]
Liu, Shaojun [3 ]
Zhu, Chen [1 ]
Shang, Da [3 ]
Guan, Yi [3 ]
Wang, Qian [1 ]
机构
[1] Fudan Univ, Huashan Hosp, Dept Hematol, Shanghai 200040, Peoples R China
[2] Inner Mongolia Med Univ, Peking Univ Canc Hosp, Dept Nucl Med, Affiliated Canc Hosp, Inner Mongolia Campus, Hohhot 010020, Peoples R China
[3] Fudan Univ, Huashan Hosp, Dept Nephrol, Shanghai 200040, Peoples R China
[4] Naval Med Univ, Changzheng Hosp, Dept Hematol Myeloma & Lymphoma Ctr, Shanghai 200003, Peoples R China
关键词
Multiple myeloma; Myeloma nephropathy; Renal impairment recovery; Risk nomogram; BORTEZOMIB-BASED CHEMOTHERAPY; CAST NEPHROPATHY; STAGING SYSTEM; HIGH-CUTOFF; FAILURE; HEMODIALYSIS; DISEASE; SAFETY; INDEPENDENCE; MULTICENTER;
D O I
10.1016/j.currproblcancer.2023.100962
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To determine risk factors affecting renal recovery in newly diagnosed multiple myeloma (NDMM) patients with renal impairment (RI) and establish a risk nomogram. This multi-center, retrospective cohort study included 187 NDMM patients with RI, 127 of whom were admitted to Huashan Hospital and assigned to the training cohort and 60 were admitted to Changzheng Hospital and assigned to the external validation cohort. The baseline data of the 2 cohorts were compared, and survival and renal recovery rates were analyzed. Independent risk factors affecting renal recovery were determined by binary logistic regression analysis, and a risk nomogram was established and subsequently tested in the external validation cohort. Results: The median overall survival (OS) improved in patients who achieved renal recovery etc within 6 courses of MM directed treatment compared with patients without renal recovery. Median time to renal recovery was 2.65 courses, and the cumulative renal recovery rate during the first 3 courses was 75.05%. Involved serum free light chain (sFLC) ratio of > 120 at diagnosis, time from renal impairment to treatment > 60 days, and a hematologic response without a very good partial remission (VGPR) or better resulted as independent risk factors for renal recovery during the first 3 courses. The established risk nomogram had good discriminative ability and accuracy. Involved sFLC was a key factor affecting renal recovery. Starting treatment as soon as possible after detecting RI and achieving deep hematologic remission during the first 3 courses of treatment helped achieve renal recovery and improve prognosis.(c) 2023 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ )
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Renal insufficiency predicts worse prognosis in newly diagnosed IgD multiple myeloma patients
    Yan, Ge
    Li, Huangmin
    Zhang, Yiding
    Xia, Chenyan
    Wang, Mengxiao
    Jia, Yu
    Shang, Jin
    Zhao, Zhanzheng
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [32] Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents
    Roussou, Maria
    Kastritis, Efstathios
    Christoulas, Dimitrios
    Migkou, Magdalini
    Gavriatopoulou, Maria
    Grapsa, Irini
    Psimenou, Erasmia
    Gika, Dimitra
    Terpos, Evangelos
    Dimopoulos, Meletios A.
    LEUKEMIA RESEARCH, 2010, 34 (10) : 1395 - 1397
  • [33] Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma
    Gonsalves, W. I.
    Leung, N.
    Rajkumar, S. V.
    Dispenzieri, A.
    Lacy, M. Q.
    Hayman, S. R.
    Buadi, F. K.
    Dingli, D.
    Kapoor, P.
    Go, R. S.
    Lin, Y.
    Russell, S. J.
    Lust, J. A.
    Zeldenrust, S.
    Kyle, R. A.
    Gertz, M. A.
    Kumar, S. K.
    BLOOD CANCER JOURNAL, 2015, 5 : e296 - e296
  • [34] Experience in treatment of newly diagnosed multiple myeloma patients with renal failure required dialysis
    Semochkin, S.
    Zhelnova, E.
    Misyurina, E.
    Tolstykh, T.
    Arkhipova, N.
    Baryakh, E.
    Grishina, E.
    Karimova, E.
    Kochneva, O.
    Mavrina, E.
    Polyakov, Y.
    Yaskova, E.
    ANNALS OF ONCOLOGY, 2018, 29
  • [35] Reversibility of Renal Failure in Newly Diagnosed Patients with Multiple Myeloma and the Role of Novel Agents
    Roussou, Maria
    Kastritis, Efstathios
    Christoulas, Dimitrios
    Migkou, Magdalini
    Gavriatopoulou, Maria
    Matsouka, Charis
    Mparmparoussi, Despina
    Grapsa, Irini
    Psimenou, Erasmia
    Gika, Dimitra
    Terpos, Evangelos
    Dimopoulos, Meletios A.
    BLOOD, 2009, 114 (22) : 394 - 395
  • [36] Recovery of renal function and independence from dialysis in newly diagnosed and relapsed multiple myeloma patients - A single instituition experience
    Ravindranathan, Girish
    Indrakumar, Tanya
    Ahmad, Sohail
    Dungarwalla, Moez
    Kanagasabapathy, Pamela
    Merceica, Jane
    Rice, Katherine
    Clarke, Mary Clarke
    Jones, Ann-Britt
    Makunjola, David
    Behrens, Judith
    BLOOD, 2007, 110 (11) : 286B - 287B
  • [37] CORRELATION OF LABORATORY DATA FOR RENAL FUNCTION IN NEWLY DIAGNOSED MULTIPLE MYELOMA
    Suzuki, Kazuhito
    Yano, Shingo
    Shimada, Takaki
    Takahara, Shinobu
    Kasama, Kinuyo
    Machishima, Tomohito
    Inui, Yumiko
    Kawashima, Masaharu
    Usui, Noriko
    Aiba, Keisuke
    ANNALS OF ONCOLOGY, 2014, 25
  • [38] Impact of age, obesity, and renal impairment on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myeloma
    Gaffney, Kelly J.
    Bakos, Jonathan K.
    Velayati, Arash
    Davis, James A.
    Thurlapati, Aswani
    Weeda, Erin
    Maldonado, Andy
    Granger, Katelynn
    Butcher, Coleen
    Herrington, Taylor
    Smith, Deidra
    Green, Kimberly
    Hess, Brian T.
    Hashmi, Hamza
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2025, 31 (01) : 72 - 80
  • [39] Renal Response of Pomalidomide with Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study
    Jian, Yuan
    Chang, Long
    Shi, Mingxia
    Sun, Ying
    Chu, Xiaoxia
    Xue, Hua
    Huang, Wenrong
    Shen, Xuliang
    Ma, Jie
    Jia, Guorong
    Peng, Yaqing
    Xi, Zhenfang
    Zhao, Yanhong
    Ma, Yanping
    Xiao, Jing
    Ma, Guangyu
    Wang, Qingming
    Bao, Li
    Dong, Yujun
    Zhou, Hebing
    Sun, Chunyan
    Su, Guohong
    Yan, Yan
    Qimuge, Saiyin
    Su, Liping
    Sun, Jingnan
    Tian, Weiwei
    Sun, Xiuli
    Jing, Hongmei
    Gao, Da
    Chen, Wenming
    Li, Jian
    Gao, Wen
    BLOOD, 2022, 140 : 10167 - 10169
  • [40] Oliguria as an early indicator of mortality risk in patients with multiple myeloma and renal impairment
    Jung, Sung-Hoon
    Ahn, Jae-Sook
    Yang, Deok-Hwan
    Cho, Min-Seok
    Kim, Jae-Yong
    Ahn, Seo-Yeon
    Kim, Yeo-Kyeoung
    Kim, Hyeoung-Joon
    Lee, Je-Jung
    BLOOD RESEARCH, 2015, 50 (03) : 167 - 172